|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanchez-Castañón M, Er TK, Bujanda L and
Herreros-Villanueva M: Immunotherapy in colorectal cancer: What
have we learned so far? Clin Chim Acta. 460:78–87. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Myint ZW and Goel G: Role of modern
immunotherapy in gastrointestinal malignancies: A review of current
clinical progress. J Hematol Oncol. 10:862017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hazama S, Tamada K, Yamaguchi Y, Kawakami
Y and Nagano H: Current status of immunotherapy against
gastrointestinal cancers and its biomarkers: Perspective for
precision immunotherapy. Ann Gastroenterol Surg. 2:289–303. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kono K: Advances in cancer immunotherapy
for gastroenterological malignancy. Ann Gastroenterol Surg.
2:244–245. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagorsen D and Thiel E: Clinical and
immunologic responses to active specific cancer vaccines in human
colorectal cancer. Clin Cancer Res. 12:3064–3069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duan Q, Zhang H, Zheng J and Zhang L:
Turning cold into hot: Firing up the tumor microenvironment. Trends
Cancer. 6:605–618. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hazama S, Nakamura Y, Takenouchi H, Suzuki
N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K,
et al: A phase I study of combination vaccine treatment of five
therapeutic epitope-peptides for metastatic colorectal cancer;
safety, immunological response, and clinical outcome. J Transl Med.
12:632014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hazama S, Nakamura Y, Tanaka H, Hirakawa
K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, et al:
A phase II study of five peptides combination with
oxaliplatin-based chemotherapy as a first-line therapy for advanced
colorectal cancer (FXV study). J Transl Med. 12:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hazama S, Takenouchi H, Tsunedomi R, Iida
M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, et
al: Predictive biomarkers for the outcome of vaccination of five
therapeutic epitope peptides for colorectal cancer. Anticancer Res.
34:4201–4205. 2014.PubMed/NCBI
|
|
15
|
Shindo Y, Hazama S, Nakamura Y, Inoue Y,
Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno
T, et al: miR-196b, miR-378a and miR-486 are predictive biomarkers
for the efficacy of vaccine treatment in colorectal cancer. Oncol
Lett. 14:1355–1362. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kijima T, Hazama S, Tsunedomi R, Tanaka H,
Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K,
et al: MicroRNA-6826 and −6875 in plasma are valuable non invasive
biomarkers that predict the efficacy of vaccine treatment against
metastatic colorectal cancer. Oncol Rep. 37:23–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanaka H, Hazama S, Iida M, Tsunedomi R,
Takenouchi H, Nakajima M, Tokumitsu Y, Kanekiyo S, Shindo Y,
Tomochika S, et al: miR-125b-1 and miR-378a are predictive
biomarkers for the efficacy of vaccine treatment against colorectal
cancer. Cancer Sci. 108:2229–2238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kitahara M, Hazama S, Tsunedomi R,
Takenouchi H, Kanekiyo S, Inoue Y, Nakajima M, Tomochika S,
Tokuhisa Y, Iida M, et al: Prediction of the efficacy of
immunotherapy by measuring the integrity of cell-free DNA in plasma
in colorectal cancer. Cancer Sci. 107:1825–1829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Crocker PR, Paulson JC and Varki A:
Siglecs and their roles in the immune system. Nat Rev Immunol.
7:255–266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fraschilla I and Pillai S: Viewing Siglecs
through the lens of tumor immunology. Immunol Rev. 276:178–191.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsumoto T, Takahashi N, Kojima T,
Yoshioka Y, Ishikawa J, Furukawa K, Ono K, Sawada M, Ishiguro N and
Yamamoto A: Soluble Siglec-9 suppresses arthritis in a
collagen-induced arthritis mouse model and inhibits M1 activation
of RAW264.7 macrophages. Arthritis Res Ther. 18:1332016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nicoll G, Ni J, Liu D, Klenerman P, Munday
J, Dubock S, Mattei MG and Crocker PR: Identification and
characterization of a novel siglec, siglec-7, expressed by human
natural killer cells and monocytes. J Biol Chem. 274:34089–34095.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Daly J, Carlsten M and O'Dwyer M: Sugar
free: Novel immunotherapeutic approaches targeting siglecs and
sialic acids to enhance natural killer cell cytotoxicity against
cancer. Front Immunol. 10:10472019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimokawa T, Matsushima S, Tsunoda T,
Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34,
which shows elevated expression in the majority of human colon
cancers, as a novel drug target. Int J Oncol. 29:381–386.
2006.PubMed/NCBI
|
|
26
|
Uchida N, Tsunoda T, Wada S, Furukawa Y,
Nakamura Y and Tahara H: Ring finger protein 43 as a new target for
cancer immunotherapy. Clin Cancer Res. 10:8577–8586. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ishizaki H, Tsunoda T, Wada S, Yamauchi M,
Shibuya M and Tahara H: Inhibition of tumor growth with
antiangiogenic cancer vaccine using epitope peptides derived from
human vascular endothelial growth factor receptor 1. Clin Cancer
Res. 12:5841–5849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wada S, Tsunoda T, Baba T, Primus FJ,
Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic
cancer therapy with vaccination using epitope peptides derived from
human vascular endothelial growth factor receptor 2. Cancer Res.
65:4939–4946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakashima-Nakasuga C, Hazama S, Suzuki N,
Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S,
Matsui H, et al: Serum LOX-1 is a novel prognostic biomarker of
colorectal cancer. Int J Clin Oncol. 25:1308–1317. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fujiwara N, Usui T, Ohama T and Sato K:
Regulation of beclin 1 protein phosphorylation and autophagy by
protein phosphatase 2A (PP2A) and death-associated protein kinase 3
(DAPK3). J Biol Chem. 291:10858–10866. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Enjoji S, Yabe R, Tsuji S, Yoshimura K,
Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S,
et al: Stemness is enhanced in gastric cancer by a SET/PP2A/E2F1
axis. Mol Cancer Res. 16:554–563. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yabe R, Tsuji S, Mochida S, Ikehara T,
Usui T, Ohama T and Sato K: A stable association with PME-1 may be
dispensable for PP2A demethylation - implications for the detection
of PP2A methylation and immunoprecipitation. FEBS Open Bio.
8:1486–1496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kuwahara T, Hazama S, Suzuki N, Yoshida S,
Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu
Y, et al: Intratumoural-infiltrating CD4+ and
FOXP3+ T cells as strong positive predictive markers for
the prognosis of resectable colorectal cancer. Br J Cancer.
121:659–665. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iizuka N, Oka M, Yamada-Okabe H, Nishida
M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, et al:
Oligonucleotide microarray for prediction of early intrahepatic
recurrence of hepatocellular carcinoma after curative resection.
Lancet. 361:923–929. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zimmerman DW: Some properties of
preliminary tests of equality of variances in the two-sample
location problem. J Gen Psychol. 123:217–231. 1996. View Article : Google Scholar
|
|
38
|
Kamarudin AN, Cox T and Kolamunnage-Dona
R: Time-dependent ROC curve analysis in medical research: Current
methods and applications. BMC Med Res Methodol. 17:532017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoshikawa K, Shimada M, Miyamoto H,
Higashijima J, Miyatani T, Nishioka M, Kurita N, Iwata T and Uehara
H: Sonic hedgehog relates to colorectal carcinogenesis. J
Gastroenterol. 44:1113–1117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu M, Li X, Liu T, Leng A and Zhang G:
Prognostic value of hedgehog signaling pathway in patients with
colon cancer. Med Oncol. 29:1010–1016. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Maréchal R, Bachet JB, Calomme A, Demetter
P, Delpero JR, Svrcek M, Cros J, Bardier-Dupas A, Puleo F, Monges
G, et al: Sonic hedgehog and Gli1 expression predict outcome in
resected pancreatic adenocarcinoma. Clin Cancer Res. 21:1215–1224.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pankov R and Yamada KM: Fibronectin at a
glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yi W, Xiao E, Ding R, Luo P and Yang Y:
High expression of fibronectin is associated with poor prognosis,
cell proliferation and malignancy via the NF-κB/p53-apoptosis
signaling pathway in colorectal cancer. Oncol Rep. 36:3145–3153.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Inufusa H, Nakamura M, Adachi T, Nakatani
Y, Shindo K, Yasutomi M and Matsuura H: Localization of oncofetal
and normal fibronectin in colorectal cancer. Correlation with
histologic grade, liver metastasis, and prognosis. Cancer.
75:2802–2808. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Miyazaki K, Sakuma K, Kawamura YI, Izawa
M, Ohmori K, Mitsuki M, Yamaji T, Hashimoto Y, Suzuki A, Saito Y,
et al: Colonic epithelial cells express specific ligands for
mucosal macrophage immunosuppressive receptors siglec-7 and −9. J
Immunol. 188:4690–4700. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dharmadhikari G, Stolz K, Hauke M, Morgan
NG, Varki A, de Koning E, Kelm S and Maedler K: Siglec-7 restores
β-cell function and survival and reduces inflammation in pancreatic
islets from patients with diabetes. Sci Rep. 7:453192017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ando M, Tu W, Nishijima K and Iijima S:
Siglec-9 enhances IL-10 production in macrophages via
tyrosine-based motifs. Biochem Biophys Res Commun. 369:878–883.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vermaelen K: Vaccine strategies to improve
anti-cancer cellular immune responses. Front Immunol. 10:82019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mlecnik B, Tosolini M, Kirilovsky A,
Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman
WH, Pagès F, et al: Histopathologic-based prognostic factors of
colorectal cancers are associated with the state of the local
immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Galon J, Mlecnik B, Bindea G, Angell HK,
Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et
al: Towards the introduction of the ‘Immunoscore’ in the
classification of malignant tumours. J Pathol. 232:199–209. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pagès F, Mlecnik B, Marliot F, Bindea G,
Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al:
International validation of the consensus Immunoscore for the
classification of colon cancer: A prognostic and accuracy study.
Lancet. 391:2128–2139. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
O'Reilly MK and Paulson JC: Siglecs as
targets for therapy in immune-cell-mediated disease. Trends
Pharmacol Sci. 30:240–248. 2009. View Article : Google Scholar : PubMed/NCBI
|
